One participant who was randomized to the 30 μg Sm-TSP-2/Alhydrogel (without AP 10–701) group became ineligible after enrollment, when it was discovered that the subject had a previously undisclosed history of chronic idiopathic urticaria; the participant was discontinued at study day 112 prior to receiving the third dose of study vaccine. This evidence concerns the gene THBS2 and chronic idiopathic urticaria.